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ABSTRACT
Human placental mesenchymal stromal cells (pMSCs) have never been investigated in intrauterine
growth restriction (IUGR). We characterized cells isolated from placental membranes and the basal
disc of six IUGR and five physiological placentas. Cell viability and proliferationwere assessed every 7
days during a 6-week culture. Expression of hematopoietic, stem, endothelial, and mesenchymal
markers was evaluated by flow cytometry. We characterized the multipotency of pMSCs and the ex-
pressionof genes involved inmitochondrial content and function. Cell viabilitywashigh in all samples,
and proliferation ratewas lower in IUGR comparedwith control cells. All samples presented a starting
heterogeneous population, shifting during culture toward homogeneity for mesenchymal markers
and occurring earlier in IUGR than in controls. In vitro multipotency of IUGR-derived pMSCs was re-
stricted because their capacity for adipocyte differentiation was increased, whereas their ability to
differentiate towardendothelial cell lineagewasdecreased.Mitochondrial content and functionwere
higher in IUGRpMSCs than controls, possibly indicating a shift fromanaerobic to aerobicmetabolism,
with the loss of the metabolic characteristics that are typical of undifferentiated multipotent cells.
STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–13
SIGNIFICANCE
This study demonstrates that the loss of endothelial differentiation potential and the increase of
adipogenic ability are likely to play a significant role in the vicious cycle of abnormal placental de-
velopment in IUGR. This is the first observation of a potential role for pMSCs in intrauterine growth
restriction, thus leading to new perspectives for the treatment of IUGR.
INTRODUCTION
Mesenchymal cells are the predominant cellular
component in placenta and serve as structural
support for trophoblast villi and vascular network
[1]. In recent investigations, human placental
mesenchymal stromal cells (pMSCs) have been
isolated according to the meeting criteria pro-
posed by the Mesenchymal and Tissue Stem Cell
Committee [2] and the International Society for
Cellular Therapy as cells that adhere to untreated
plastic surfaces and express CD105, CD73, and
CD90 but not CD34, CD14, CD19, CD11b,
CD79a, or HLA-DR and that differentiate into os-
teogenic, adipogenic, and chondrogenic lineages
in vitro [3, 4]. Both fetal (from placental mem-
branes and villi) and maternal (from decidua)
pMSCs can be isolated from the human placenta,
showing similar phenotypes [5–8]. Indeed, the
placental maternal side comprises the chorionic
villi on one side and maternal decidua on the
other. The peripheral region of the placenta on
the maternal side that is in contact with the uter-
inewall (called thebasal plate) comprises the cho-
rionic villi on one side and maternal decidua
basalis on the other. The significant issue of the
presence of maternal cells in human pMSCs cul-
tures was reviewed recently [9].
Despite progress in the characterization of
pMSCs, it remains largely unknown to what de-
gree the pMSCs are involved in placenta disease.
Investigation of pMSCsmay therefore give impor-
tant hints for pregnancy pathologies linked to pla-
cental insufficiency, namely intrauterine growth
restriction (IUGR) and preeclampsia (PE) [10].
IUGR and PE are leading causes of maternal and
neonatal morbidity and mortality [11, 12]. A spe-
cific placental phenotype has been associated
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with IUGR [13], characterized by altered transport of oxygen and
nutrients [14–17] and impaired mitochondrial content and func-
tion [18, 19]. We recently showed altered mitochondrial content
and functionality in cytotrophoblast cells isolated from IUGR pla-
centas [11] suggesting compensatory mitochondrial mechanisms
that occur under placental vascular insufficiency. Indeed, IUGR
placentas present defective vascular transformation and terminal
villous formation, with fewer and thinner villi and vessels, espe-
cially in the most severe cases, that are differently distributed
along the placental surface, as reviewed by Gourvas et al. [20].
Only a few studies have focused on the role of pMSCs in pla-
cental insufficiency, and all of themhave addressed preeclampsia
[1, 21–25]. Human pMSCs isolated from PE placentas and de-
ciduas display decreased proliferation and, interestingly, show
proinflammatory and antiangiogenic characteristics [21, 24, 25]
that lead to impairment of trophoblast development and invasive
capacity and to defects in placental vasculogenesis. Currently, no
data have been reported on pMSCs in IUGR.
Here we hypothesize that pMSC phenotype may be involved
in the pathogenesis of IUGR. Thus, we performed a study to iso-
late human pMSCs residing in physiological and IUGR placentas
and to characterize them in vitro, in reference to their immuno-
phenotype, cell viability, expansion rate, differentiation poten-
tial, and mitochondrial content, in order to evaluate their
potential involvement in IUGR placental phenotype.
MATERIALS AND METHODS
Study Population
Pregnant women were enrolled in the Unit of Obstetrics and Gy-
necology of the L. SaccoHospital inMilan, Italy. The studywas ap-
proved by the institutional ethics committee, and samples were
collected with the informed consent of the patients. Human pla-
centas were obtained at elective cesarean delivery (nonlaboring
deliveries) from 11 singleton pregnancies.
We studied six pregnancies complicated by IUGR between 32
and 37 weeks of gestation. Gestational age was calculated from
the last menstrual period and was confirmed by routine ultraso-
nography at 11–12 weeks of gestation. We identified growth-
restricted fetuses in utero through repeated longitudinal mea-
surements that demonstrated a reduction in fetal growth velocity
[17, 26, 27]. Specifically, IUGR was defined by measurements of
abdominal circumferencesbelowthe10thpercentile of reference
values for fetuses of similar ages together with a shift from the
growth curve greater than 40 centiles [28]. As an example, this
represents a decrease from the 50th centile (measured at 20
weeks) to below the 10th centile (at the time of IUGR diagnosis).
Growth restriction was confirmed at birth if the neonatal weight
was below the 10th percentile according to Italian standards for
birth weight and gestational age [29].
Healthy controls (n = 5) were term ($37 weeks) physiological
pregnancieswith normal intrauterine growth and appropriate for
gestational age birth weight, according to reference ranges for
the Italian population [29]. Exclusion criteria were any placental
or fetal disease. Indications for cesarean delivery before labor
were breech presentation, previous caesarean deliveries, or ma-
ternal request. Exclusion criteria for both groups were maternal
drug or alcohol abuse and autoimmune diseases. None of the
fetuses had abnormal karyotype, genetic syndromes, viral infec-
tion, or major malformations.
Sample Collection, Isolation, and Expansion of Cells
Derived From Physiological and IUGR Placentas
Placental tissuewas collected immediately after cesarean delivery
and rapidly rinsed in phosphate-buffered saline (PBS) containing
penicillin (200 U/ml) and streptomycin (200 mg/ml) for cell exper-
iments. Placentaswereweighed after discardingof the cord,mem-
branes, and excess blood. Full-thickness pieces, 1.5 cm3, were
sampled in different sites of the placental disc and washed in
Hanks’ balanced saline solution (Sigma-Aldrich, St. Louis, MO,
https://www.sigmaaldrich.com). After mechanical separation of
placental membranes (PM) from the placental basal disc (PBD),
these tissueswereenzymatically digestedwith collagenase IA (Invi-
trogen, Life Technologies, ThermoFisher Scientific, Carlsbad, CA,
https://www.thermofisher.com) and trypsin 2.5% (Invitrogen, Life
Technologies, ThermoFisher Scientific, ) and incubated in a fully hu-
midified atmosphere of 5% CO2, 95% air, at 37°C for 45 minutes.
Digested tissues were then filtered and centrifuged at 2000
rpm for 10 minutes, and cells were grown in expansion medium
as previously described [30] with the following minor modifica-
tions. PM- and PBD-derived cells were plated in six-well tissue cul-
ture plates (VWR, Radnor, PA, https://vwr.com), coated with 0.2%
gelatin (Sigma-Aldrich), at a density of 104 cells/well. Cells were
grown in expansionmedium composed of Dulbecco’smodified Ea-
gle’s medium/F-12 (1:1) (Invitrogen, Life Technologies, Thermo-
Fisher Scientific), 10% fetal bovine serum. and 20 ng/ml
epidermal growth factor (Miltenyi Biotec, Bergisch Gladbach, Ger-
many, http://www.miltenyibiotec.com/en). Expansion cultureme-
dia were prepared fresh weekly. Cells were incubated in a fully
humidified atmosphere of 5% CO2, 95% air, at 37°C for several
weeks.Everyweek, livingcellswerecountedwithaBurker chamber
using trypan blue (Sigma-Aldrich) exclusion method.
Cellswere counted and passaged at a confluence of 70%–80%
for up to 6weeks of culture. At each passage, the population dou-
bling (PD) rate was determined by using the formula doubling
time = ln(2)/proliferation index, where the proliferation index
is calculated as N(t) = the number of cells at time t/the number
of cells at time of previous passages (t2 7days). The PD of each
passage was calculated and added to the PD of the previous pas-
sages to generate the cumulative population doubling rate. All
counts were performed in triplicate, and data are shown asmean
fold (6SD in percentages of four experiments).
To assess proliferation and viability, samples were analyzed by
MTT (3-[31]-2,5-diphenyltetrazolium bromide) activity assay [31]
andexpressedaspercentageof viable cells on the total cell number.
Values are expressed as means6 of three separate experiments.
Colony-Forming Unit Assays
PM- and PBD-derived pMSC cells (53 103) fromphysiological (n = 5)
and IUGR (n = 6) placentas were used for the colony-forming unit-
fibroblast (CFU-F) assay. Cells were plated in expansion medium in
duplicate in six-well plates. After 14 days of culture in a humidified
incubatorat37°Cand5%CO2, thecolonieswerestainedwith1%crys-
tal violet solution for 5–10minutes andwashed twicewith deionized
water.Aggregatesof cellswithadiameterbetween1and8mmwere
identified as colonies and counted under a light microscope (Leica
DM6000R, Leica Microsystems, Renens VD, Switzerland, http://
www.leica-microsystems.com/)using thesoftware Image-J (National
Institutes of Health, Bethesda, MD, http://imagej.nih.gov). pMSCs
were also cultured in methylcellulose as described in the
supplemental online data.
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FACS Analysis of Cells Isolated From Physiological and
IUGR Placentas
At 24 hours, 7 days, and 30 days, 105 cells were incubated with
7-amino-actinomycin D (7AAD; used to analyze only live cells [BD
Biosciences/Pharmingen, San Jose, CA, https://www.bdbiosciences.
com) and with the following antibodies: anti-CD34-allophycocyanin
(APC) and anti-CD45-APC-CY7 (hematopoietic stem cell markers);
anti-CD31-fluorescein isothiocyanate (FITC) (endothelial cell marker);
and anti-CD44-FITC, anti-CD105-phycoerythrin (PE), anti-CD29-FITC,
anti-CD73-APC, and anti-CD90-PE-Cy5 (mesenchymal cell markers)
(Miltenyi Biotec). Isotype-matched mouse immunoglobulins were
used as negative controls. After each incubation, performed at 4°C
for 20 minutes, cells were washed in PBS, 1% heat-inactivated FCS,
and 0.1% sodium azide. Cytometric analyses were performed with
a Cytomics FC 500 flow cytometer and 2.1 CXP software (Beckman
Coulter, Brea, CA, https://www.beckmancoulter.com). Each analysis
included at least 10,000–20,000 events for each gate. A light-
scatter gate was set up to eliminate cell debris from the analysis.
The percentage of positive cells was assessed after correction for
the percentage reactive to an equivalent isotype control.
Cytogenetic Analysis
PM-andPBD-derivedpMSCcells (53103) fromphysiological (n=3)
and IUGR(n=2)placentasweretestedbychromosomeanalysisand
real-time polymerase chain reaction (PCR) for Y chromosome (SRY)
as described in the supplemental online data.
In Vitro Differentiation of pMSCs Isolated From
Physiological and IUGR PM and PBD Tissues
Myogenic Differentiation
After in vitro proliferation, human pMSCs were plated in 24-well
tissue culture plates, coated with 10 mg/ml laminin (Sigma-
Aldrich), in expansion medium. After 3–5 days (70%–80% conflu-
ence), theywere switched in low-serum(DMEM,2%horse serum)
fusion-promoting medium for myogenic differentiation. After 14
days of culture, differentiated muscle cells were detected by
immunostaining with antibodies against a-smooth muscle actin
(a-SMA; 1:50 dilution, mouse anti-human; Sigma-Aldrich) and
desmin (1:50 dilution, rabbit polyclonal; Abcam Inc., Cambridge,
MA). Nuclei were counterstained with 49,6-diamidino-2-phenylindole.
Images were captured using the Leica TCS SP2 confocal system
(Leica Microsystems) at 18–20°C.
Osteogenic, Chondrogenic, and
Adipogenic Differentiation
Osteogenic, chondrogenic, and adipogenic potential of pMSCs
was verified through the use of specific differentiation kits: hMSC
Osteogenic BulletKit, hMSC Chondro BulletKit, and hMSC Adipo-
genic BulletKit (Lonza, Basel, Switzerland, http://www.lonza.
com) (supplemental online data).
Tubulogenesis Assay
Expanded human pMSCs were incubated in an endothelial
growth medium containing medium 199 (Gibco-BRL, Life Tech-
nologies, ThermoFisher Scientific) supplemented with 50 ng/ml
vascular endothelial growth factor (VEGF). Cells were seeded at
a density of 30,000 cell/cm2 on six-well plates coated with Matri-
gel (Corning, Corning, NY, https://www.corning.com/medium)/
199medium (1:1) and incubated in a humidified atmospherewith
5% CO2, 95% air, at 37°C. After 24 hours, we observed the forma-
tion of capillary-like tube structures by using an inverted micro-
scope (Leica DMIRE2). Manual tube identification was
performed using ImageJ software. To depict the beginning and
ending points of individual tubes on the processed image, three
different operators processed four selected images. As result of
this process, a tube topology graph was formed that enables
thegathering of valuable statistics, such as total tube length. Tube
length was compared in normal and IUGR differentiated pMSCs.
Human fibroblast cells were used as a negative control. To con-
firm tubulogenesis, immunostaining with antibody against von
Willebrand factor (vWF; diluted 1:50, Dako, Glostrup, Denmark,
http://www.dako.com) was performed on capillary-like tube
structures. Images were captured by using an inverted micro-
scope (Leica DM 6000R). Endothelial differentiation was con-
firmed by real-time PCR analysis of CD31 expression levels.
Each experiment was performed in triplicate, and for each sam-
ple, the median value between the three experiments was
reported.
Angiogenic Potential of pMSCs Isolated From Human
Physiological and IUGR Placentas
We investigated the angiogenic potential of pMSCs isolated from
physiological and IUGR PMand PBDby using a directed in vivo an-
giogenesis angioreactor (DIVAA) as described in supplemental
online data [32].
Gene Expression Analysis of Mitochondrial Biogenesis
Activator and Respiratory Chain Complexes
pMSCs were analyzed for the expression ofmitochondria-related
genes after approximately 30 days of culture in expansion me-
dium. Total RNA was extracted by TRIzol Reagent (Ambion, Life
Technologies, ThermoFisher Scientific). After DNase I treatment
(New England Biolabs, Ipswich, MA, https://www.neb.com),
aimed at removing potentially contaminatingDNA, 1.6mg of total
RNA were reverse-transcribed by using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Life Technologies,
ThermoFisher Scientific) with random examers. Gene expression
ofUQCRC1, COX4I1 (two subunits respectively belonging to the III
and IV respiratory chain complexes), and NRF1 (a mitochondrial
biogenesis activator) was analyzed by real-time PCR using the
7500 Fast Real-Time PCR System with TaqMan assays (Applied
Biosystems, Life Technologies, ThermoFisher Scientific). Expres-
sion levels were determined according to the E-DCt/NF formula
(GeNorm method [33]), which considers the assay amplification
efficiency (E, calculated froma serial dilution curve) and a normal-
ization factor (NF) relative to PPIA and RPL13A control genes. All
sampleswere reverse-transcribed in duplicate, and cDNAwas run
in triplicate.
RESULTS
Clinical Data of the Study Population
Individual clinical data of patients included in this study are pre-
sented in supplemental online Table 1. No significant differences
emerged between groups for maternal age and prepregnancy
BMI.As expected, gestational age, andplacental and fetalweights
were significantly lower in IUGR than physiological pregnancies.
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Figure 1. Characterization and proliferation of placental mesenchymal stromal cells (pMSCs). (A–D):Morphology of pMSCs at passage 3 iso-
lated fromthe indicatedplacental compartment (physiological,n=5; IUGRn=6)observedbyphase-contrastmicroscopy (originalmagnification,
310). Fluorescent in situ hybridization analysis shows a male pattern (E, F), a mixed male/female pattern (G), and a female pattern (H). (I):
Viability of cells isolated from physiological (n = 5 each group) and IUGR (n = 6 each group) PM and PBD placentas after 6 weeks of culture
in proliferationmedium.DXZ1 (Xp11.1q11.1) spectrum green; SRY (Yp11.3) spectrum orange. (J): Expansion rate of the same samples observed
during 6weeks of culture obtainedby visual counting after trypanblue staining. Data are shownas average6 SD (in percentages) of 11placental
samples, each performed in three replicates. p, p, .01; ppp,p, .001. (K): Proliferative potential of pMSCs isolated fromphysiological and IUGR
PM and PBD cultured at passage (P3) was measured by 3-[31]-2,5-diphenyltetrazolium bromide assay after 0, 1, 2, 4, and 7 days of seeding. (L):
Measurements of doubling rate every 7 days, during the entire culture period, based on visual count after trypan blue staining. (M): Crystal
violet-stained plates of colony-forming units-fibroblast (CFU-F) assays performed on P3 pMSCs isolated from physiological and IUGR PM
and PBD. (N): Representative phase-contrast microscopic images of single CFU-F assay of P3 pMSCs from physiological and IUGR PM and
PBD stained by crystal violet (original magnification,34). (O): CFU-F assay analysis. The data represent the mean6 SEM number of colonies
per plate. Abbreviations: IUGR, intrauterine growth restriction; PBD, placental basal disc; PM, placental membrane.
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Morphologic and Cytogenetic Analysis of PM and
PBD-Derived Cells Isolated From Physiological and
IUGR Placentas
Cells were isolated from PM and PBD tissues and cultured in ex-
pansion medium. PM- and PBD-derived cells adhered to plastic
and showed a typical fibroblastic morphology of MSC by light mi-
croscopy (Fig. 1A–2D).
Given the risk for cross-contamination between fetal and ma-
ternal cells, we first analyzed physiological (n = 3) and IUGR (n = 3)
PM- and PBD-derived cells by fluorescence in situ hybridization
(FISH) to verify that pure cell populations had been isolated. For
these experiments, PM- and PBD-derived cells were isolated from
placentae of women delivering a male baby, and approximately
200 cells of each typewere analyzed for signals in interphase nuclei
using X/Y chromosome probes. Cells derived from PM showed the
XY phenotype (spectrum green and orange-labeled chromosomes,
respectively) and were therefore 100% male (Fig. 1E, 1F) as previ-
ously described [34]. Two spectrum green-labeled X chromosomes
were visible in cells derived from PBD with a low contamination
(,5%) of XY phenotype; therefore, these cells were prevalently
of maternal origin (Fig. 1G, 1H), in agreement with the literature
[9,35].Real-timePCRwithprimers for theSRYgeneconfirmedthese
data (data not shown).
PM- and PBD-Derived Cells Isolated From Physiological
and IUGR Placentas Showed Mesenchymal Features
High cell viability was reported for 6 weeks (P5) for all the ana-
lyzed samples, confirming appropriate culture conditions (Fig.
1I). Cell proliferation was also monitored by using theMTT assay.
After three passages (P3), PM- and PBD-derived cells isolated
fromphysiological and IUGRplacentas showed similar rate of pro-
liferation (Fig. 1J, 1K) and became more homogeneous following
expansion with a fibroblastic morphology characteristic of MSCs
(Fig. 1). Otherwise, in long-term culture conditions (for 35 days;
after P5) the IUGR PM- and PBD-derived cells displayed a lower
proliferation rate and doubling time compared with healthy con-
trols (Fig. 1L). Because placenta cultured cells were morphologi-
cally indistinguishable after passaging from MSC phenotype, it
was crucial to characterize these cells for theMSC surfacemarker
expression. Flow cytometry analysis demonstrated that 24 hours
after isolation, all samples presentedaheterogeneouspopulation
composed of different cell types (Figs. 2, 3), whereas after 7 days
of culture PM and PBD cells acquire a homogenous immunophe-
notype. In particular, the number of contaminating hematopoietic
cells expressing the CD34 and CD45 markers progressively di-
minished to less than 1% after passaging (Fig. 2), withmore cells
positive for CD105, CD29, CD73, and CD44 mesenchymal markers
(Fig. 3), indicating a progressive enrichment of pMSC.
To verify the presence ofMSCs, PM- and PBD- (n = 3 per group)
derived cells from IUGR and physiological placentas at P3 were
assayed for their capacity to develop colony forming unit fibroblast
(CFU-F) colonies (Fig. 1M–1O). Few colonies were counted in all
sampleswith a non–statistically significant prevalence in physiolog-
ical versus IUGR PMCFU-F (23.836 6.24 vs. 17.586 5.55; p = .07),
whereas a statistically significantly increased number of colonies
was found in physiological versus IUGR PBD CFU-F (37.89 6 4.1
vs. 8.366 5.75; p, .0001). Methylcellulose colony assays demon-
strated the absence of hematopoietic colony forming unit granulo-
cyte (CFU-G), colony forming unit-monocyte (CFU-M), and colony
forming unit-granulocyte macrophage (CFU-GM) colonies after
P3(datanotshown), suggestingasimultaneous lossofhematopoietic
stem cell and pMSC enrichment in our culture system.
The enrichment of pMSCs occurred earlier in IUGR than in
healthy samples (Fig. 3A–3F): (a) PM-derived cells from IUGR and
healthy samples were CD105/CD29 (18.8% 6 1% and 10% 6 2%,
respectively; p , .05) and CD73/CD44 (50% 6 47% and 5% 6
1% respectively, p , .05), and (b) PBD-derived cells from IUGR
and healthy samples were CD105/CD29 (9.5% 6 1% and 1.6% 6
0.2% respectively; p, .05) and CD73/CD44 (4%6 0.5% and 2%6
0.1% respectively; p, .05) (Fig. 3). After 7 days of culture, the per-
centage of PM- and PBD-derived cells with mesenchymal immuno-
phenotype was, respectively, 1.6–4-fold (Fig. 3C) and 2.3–5.8-fold
(Fig. 3F) higher in IUGRcomparedwithhealthy controls.Differences
turned out to be statistically significant for CD105, CD44, CD73, and
CD90 (p, .05) and for CD29 (p, .001) expression in PM-derived
cells (Fig.3C)andonly forCD29(p, .05) inPBD-derivedcells (Fig.3F).
After 30 days of culture, all PM- and PBD-derived cells were pos-
itive for typical MSC markers CD44, CD105, CD29, CD90, and
CD73 (Fig. 3A–3F) and were negative for CD31 endothelial
marker (data not shown). Overall, the datawere consistent with
the expression profile stipulated for pMSCs.
Multipotency of pMSCs
Differentiation of expanded pMSCs from PD and PBD of healthy
and IUGR placentas into osteogenic, adipogenic, and chondrogenic
lineages was examined to further verify their in vitro MSC proper-
ties. Alizarin red-stained calcium deposits indicative of bone forma-
tion were visible in pMSCs of all samples maintained in osteogenic
induction medium (Fig. 4A). Oil Red O-stained lipid droplets were
observed around cell nuclei in pMSCs stimulated in adipogenic dif-
ferentiationmedium(Fig.4A–4C). In this condition, the IUGRpMSCs
differentiated 1.7-fold more than did physiological ones, as con-
firmed by the number of cells expressing fatty acid binding protein
4 (FABP4) and perilipin A (data not shown). In chondrogenic condi-
tions, the pMSCs were positive for alcian blue staining (Fig. 4A);
however, no significant differences were observed between the
healthy and IUGR PD and PBD groups. To determine whether IUGR
affectedpMSCmultipotencymorebroadly,weevaluated theability
of pMSCs to differentiate into other cell types, specifically muscle
cells. Human desmin and a-SMA-positive myotubes were formed
in both IUGR and physiological groups on day 10. No significant dif-
ferences were observed in the percentages of desmin-expressing
cells/total nuclei when the two groups were compared (data not
shown). Collectively, these in vitro findings demonstrate the multi-
potency of healthy and IUGR-derived pMSCs and a prevalence of
adipocyte differentiation in IUGR pMSCs.
In Vitro and In Vivo Angiogenic Potential of pMSCs
Isolated From Physiological and IUGR Placentas
Under endothelial growth medium, we observed thicker capillar-
ies, creating a complex network predominantly in PBD-derived
pMSCs (Fig. 5A). The specificity of the observed capillary struc-
tureswas confirmedby their complete positivity for vWFandneg-
ativity of fibroblast cells used as negative control (Fig. 5A).
Moreover, endothelial tubular structures were highly reduced
inPM-andPBD-derivedpMSCs from IUGRcomparedwithhealthy
specimens (Fig. 5A). Indeed, the formation rate of the tubular
structures during 72 hours of culture and their length (Fig. 5B)
remained significantly lower in IUGR pMSCs than those in physi-
ological ones (p , .05). Real-time PCR analysis confirmed
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Figure 2. Flow cytometry analysis for hematopoietic antigen expression in placental mesenchymal stromal cells (pMSCs). FACScan (BD Bio-
sciences, Franklin Lakes, NJ, http://www.bdbiosciences.com) immunophenotyping of human placental membrane- and placental basal disc
(PBD)-derived cells of physiological (n = 5 each group) and IUGR (n = 6 each group) placentas. Histograms show representative examples of
placental cells isolated stained with cell surface markers. Hematopoietic markers expression was analyzed 24 hours after isolation and after
7 and 30 days of culture (A, B). pMSCs expressed hematopoietic markers after 24 hours of culture, which decreased considerably after 7
and30daysof culture. The reductionofCD34andCD45hematopoieticmarkers expressionwasmoreevident inpMSC isolated fromPBD-derived
cells of physiological and IUGR placentas (B). Abbreviations: APC, allophycocyanin; IUGR, intrauterine growth restriction; SSC, side scatter.
6 Placental MSC Impairment in IUGR
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
 by A
lessandro Rolfo on M
arch 11, 2016
http://stem
cellstm
.alpham
edpress.org/
D
ow
nloaded from
 
Published Ahead of Print on March 8, 2016 as 10.5966/sctm.2015-0155. 
statistically significantly higher CD31expression (p, .05) in phys-
iological compared with IUGR differentiated pMSCs (Fig. 5C).
Theangiogenic effect ofpMSC isolated fromphysiological and
IUGR placental membranes and placental basal discs was evalu-
ated indirectly by incubating pMSC-conditioned media with a
human umbilical vein endothelial cell (HUVEC) cell line. After
24 hours, we observed a higher, non–statistically significant for-
mation of capillary-like tube structures in PBD than PM-derived
mediumconditions (Fig. 5D). To further extend these in vitrodata,
we performed in vivo experiments using a previously described
Figure 3. Flowcytometry analysis formesenchymal antigen expression in placentalmesenchymal stromal cells (pMSCs). FACScan (BDBiosciences)
immunophenotyping of human placental membrane (PM)- and placental basal disc (PBD)-derived cells of physiological (n = 5 each group) and in-
trauterine growth restriction (IUGR) (n = 6 each group) placentas. (A, B, D, E): Histograms show representative examples of pMSCs isolated from
passage 3 stainedwithmesenchymal cell surfacemarkers. Coexpression of CD105/CD29 and CD44/CD73 increased during PMand PBD cell culture.
At day 7, mesenchymal markers were 1.6–4-fold (membranes) and 2.3–5.8-fold (basal disc) higher in IUGR placentas compared with controls. Dif-
ferences were statistically significant for CD105, CD44, CD73, and CD90 (p, .05) and for CD29 (p, .001) in placental membranes (C) and only for
CD29 (p, .05) in placental basal disc (F). p, p, .05; ppp, p, .001. Moreover, dot plots show representative examples of coexpression of more
significant mesenchymal markers, such as CD105+ CD29+ and CD44+CD73+ at different days of culture (G–J). After 30 days, all samples showed a
typical homogeneous immunophenotype of mesenchymal stromal cells. Abbreviations: FITC, fluorescein isothiocyanate; PE, preeclampsia.
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reproducible andquantitative angiogenesis assay (DIVAA system)
[32]. Fifteen days after subcutaneous implantation in nude mice,
the angioreactors containing IUGR and physiological pMSCs
showed numerous blood vessels positive for vWF expression
(Fig. 6). A well-organized network of vessels was found in the
fibroblast growth factor-2-positive control (8.8 6 2.4) and in
the samples containing pMSCs derived from PM and PBD physi-
ological (27.468.4and25.363.2 respectively) and IUGR (10.66
2.8 and 8 6 1.6 respectively) samples (Fig. 6). Few endothelial
structureswere also found in theMatrigel-negative control group
(56 1.4) (Fig. 6). All these data suggest an impaired endothelial
potential of IUGR pMSCs.
Figure 4. Placental mesenchymal stromal cell (pMSC) multilineage differentiation in vitro: osteogenic, chondrogenic, adipogenic, andmyogenic
commitment. pMSC isolated from placenta membrane and placental basal disc physiological (n = 5 each group) and IUGR (n = 6 each group) pla-
centas at passage 3were investigated for their in vitromultilineage differentiation capacity. (A):Osteogenesiswas demonstrated by enhancement
of the alizarin red staining.Chondrogenesiswas indicatedbyalcianblue staining in cryosections frompMSCs.Desmin (green)anda-smoothmuscle
acti (red) staining confirmed their myogenic differentiation. Nuclei were stained blue with 49,6-diamidino-2-phenylindole. Adipogenesis was de-
tected by the formation of neutral lipid vacuoles stainable with Oil-Red O (for all representative examples, original magnification, 310). (B, C):
AdipogenicdifferentiationwasquantifiedbyspectrophotometricmeasurementswithOil RedO levels.p,p, .05.Abbreviations:adipo, adipogenic;
chondro, chondrogenic; Dapi, 49,6-diamidino-2-phenylindole; IUGR, intrauterine growth restriction; myo, myogenic; osteo, osteogenic.
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Activation of Respiratory Mitochondria-Related Genes
in IUGR pMSCs
Because we observed a reduced endothelial potential in IUGR
pMSCs, we hypothesized that environmental placental hypoxia
may influence the respiratory mitochondria gene expression of
these cells. Indeed, recent literature demonstrated that mitochon-
drial dysfunction also represents a critical factor for fetal program-
ming in cases of placental insufficiency [36]. We therefore
investigated the expression levels of the respiratory chain genes
UQCRC1 and COX4I1 and of the mitochondrial biogenesis activator
NRF1 in IUGR(n=3)andphysiological (n=3)pMSCs. IUGRcompared
with physiological pMSCs displayed a trend toward higher levels of
all analyzed genes in the PBD and of COX4I1 in PM groups (p, .05)
(Fig. 7). Thesedatamay suggest a role of the pMSCs in IUGR and are
in agreement with our previously reported results [18].
DISCUSSION
Herewe report for the first time pMSC proliferation and differen-
tiation characteristics in human IUGR pregnancies.Mesenchymal
marker enrichment and multipotent differentiation abilities con-
firmed successful isolationandselectionofamesenchymal stromal
cell population frommembranes and basal disc of both physiolog-
ical and IUGR placentas. As attested by flow cytometry data, the
pMSC population was selected earlier in IUGR placentas, although
initial cell type proportions were similar in the two groups. More-
over, this population displayed lower endothelial and higher
adipogenic differentiation potentials comparedwith normal con-
trols.We found lower proliferation rate in IUGRpMSCs compared
with controls, especially after 35 days of culture.
A significant decrease in pMSC proliferation rate has been
previously reported in PEwith fetal and/or placental compromise
compared with physiological pregnancies [24]. Authors hypothe-
sized that this pMSC reduction could impair primary villi forma-
tion and trophoblast development during placentation because
pMSCs both serve as structural support and exert a paracrine ac-
tivity on trophoblast cells. Thus, this could contribute to the ab-
normal villous architecture found in PE [1, 24]. Decreased
proliferation was also found in MSCs isolated from PE deciduas,
and linked to microRNA-16 (miR-16) overexpression leading to
Figure 5. Tubulo formation assay. Endothelial differentiation potential of pMSCswas analyzed by immunofluorescent and immunohistochem-
istry assays. (A): Phase-contrast morphology of PM-derived pMSCs isolated from physiological (n = 5) and IUGR (n = 6) and PBD-derived pMSCs
isolated fromphysiological (n=5) and IUGR (n=6) andhuman fibroblasts used as negative control after 72hours of two-dimensional endothelial
differentiation (original magnification,310). Physiological pMSCs formed more capillary-like tube structures than IUGR pMSCs. In fibroblast
cells, we never observed tubular structures. These data were confirmed by quantification of endothelial differentiation, measuring tube-like
structure length (B), histological colorationwith vWF (A), andCD31expressionby real-timepolymerase chain reaction analysis (C).p,p, .05;pp,
p, .005; ppp, p, .001. The angiogenic effect of pMSCs was indirectly measured by incubating pMSC-conditioned medium with human um-
bilical vein endothelial cell line in aMatrigel tube formation assay (A) and quantified bymeasuring tube-like structure length (D). Abbreviations:
IUGR, intrauterine growth restriction; CTR-, negative control; Endo medium, two-dimensional endothelial differentiation; PD, placental basal
disc; PM, placental membrane; pMSCs medium, placental mesenchymal stromal cell-conditioned medium; vWF, von Willebrand factor.
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cyclin E1 downregulation. High miR-16 levels also caused VEGF
subtype A and decreased secretion and led to consequent reduc-
tion of trophoblastmigration, HUVECmigration, and blood vessel
formation. It was therefore suggested that abnormal decidual
MSCs overexpressing miR-16may be involved in PE development
by altering the pregnancy microenvironment that influences an-
giogenic processes [25].
As attested by flow cytometry, in IUGR placentas the mesen-
chymal stromal cell population is selected earlier than seen with
controls. This suggests that in the pathological tissue-specific con-
ditionsmight occur so thatmesenchymal stromal cells aremore re-
sistant and selected faster. However, IUGR pMSCs showed a low
rate of proliferation and altered differentiation capacities toward
endothelial and adipogenic lineages. Thus, the faster selection of
themesenchymal cell type in IUGR culturesmight represent a com-
pensatory mechanism to metabolic alterations occurring in IUGR
placental cells and/or to the adverse IUGR placental environment.
Our data showed lower endothelial differentiation potential
of pMSCs isolated from IUGR placentas compared with healthy
controls. Placental mesenchymal cells have been proposed to
play an important role in placental vascularization during the
whole human pregnancy by contributing both to vasculogenesis
and angiogenesis, which are critical for placental development
[20]. Abnormal vasculogenesis and angiogenesis are correlated
with the impaired placental and fetal development observed in
complicated pregnancies, such as IUGR [20]. Interestingly, in vitro
studies showed that IUGR placental villous stromal cells altered
ability to stimulate endothelial tubule-like structure formation
and migration [37]. In addition, the imbalance between pro-
and antiangiogenic factors is well documented in placentas and
in maternal blood of IUGR and PE pregnancies, suggesting a role
in their pathophysiology [38, 39]. Endothelial progenitors contrib-
ute to tissue regeneration by induction of new vessels, thereby
increasing tissue perfusion and oxygenation [40, 41]. The
Figure 6. Angiogenic potential of placental mesenchymal stromal cells (pMSCs) isolated from human physiological and intrauterine growth
restriction (IUGR) placentas. Quantification of angiogenic activity of PM- and PBD-derived pMSCs isolated from physiological and IUGR per-
formed by the DIVAA system. (A): Angioreactors were recovered at 15 days after subcutaneous implantation. Unlike the control angioreactors
with no angiogenic factor (B), assays containing an angiogenic factor (fibroblast growth factor-2 [FGF-2]) (C) andhumanpMSCsonly (D) revealed
numerous blood vessels near the open end that invade theMatrigel. Sections of paraffin-embedded angioreactor containing pMSCs stained by
hematoxylin and eosin (H&E) (E) (originalmagnification,310), andH&E staining of angioreactor containing physiological and IUGRPBD-derived
pMSCs (F, G) and physiological and IUGR PM-derived pMSCs (H, I) (original magnification, 340). Matrigel invasion and early organization of
endothelial cell-containing structures is revealed by vWF (in red) (angioreactor only [J], angioreactor plus FGF-2 [K], and the angioreactor with
physiological and IUGRPBD-derivedpMSCs [L,M]). PBD-derivedpMSCs isolated fromphysiological and IUGRspread throughout the surfaceand
aligned to formbranching, anatomizing tubeswithmulticentric junctions that formed a closely knitmeshwork of capillary-like structures (L,M).
The number of vonWillebrand factor-positive vessels represented in (N)was obtained by counting six fields at original magnification,320 (p, p
, .05; pp, p , .005). Abbreviations: DIVAA, directed in vivo angiogenesis angioreactor; PD, placental basal disc; PM, placental membrane.
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formation of these networks is important for organogenesis dur-
ing fetal development. Indeed, endothelial progenitor cells play a
critical role in blood vessel formation and vascular homeostasis
and can also lead to tissue disorganization and fibrosis, as
reviewed by Piera-Velazquez et al. [42].
Interestingly, several studies have pinpointed alterations in
maternal and fetal endothelial progenitor cells [43, 44]. The
mechanisms underlying impaired neovascularization in feto-
placental circulation occurring in IUGR still need to be clarified
andmaybeassociatedwith the reduced capacity of pMSCs to give
rise to differentiated endothelial cells. Unlike endothelial differ-
entiation capacity, we found increased adipogenic potential in
IUGR pMSCs compared with controls. To our knowledge, pMSC
adipogenic potential has never been quantitatively assessed in
the pathologic human placenta. However, IUGR newborns have
increased risk for adult obesity and metabolic syndrome [45].
Inanimalmodelsof IUGR, several alterations involvingboththe
adipose tissue structure and endocrine system have been demon-
strated. Changes in central nervous system appetite control and
hormone secretion and regulation, as well as an increase of
adipocyte differentiation, have been shown in IUGR rat offspring,
as reviewed by Desai and Ross [45]. Because these changes are ev-
ident early in life, the predisposition to obesity may be pro-
grammed in utero, as already hypothesized in the “fetal
programming” theory [46], possibly through altered epigenetic
mechanismsasrecently reported in ratoffspring [47].Mitochondri-
al dysfunctions also represent a critical factor for fetal program-
ming in cases of placental insufficiency [36]. Diaz and colleagues
showed the link between fetal growth restraint and placental mi-
tochondrial dysfunction, as reflected by changes in mitochondrial
DNA (mtDNA) content and superoxide dismutase activity [48].
Because we previously demonstrated that mtDNA content
was high in IUGR placentas [18], we investigated the gene expres-
sion levels of the mitochondrial respiratory chain genes UQCRC1
and COX4I1 (respectively belonging to the III and IV respiratory
chain complex) and of the mitochondrial biogenesis activator
NRF1 of IUGR and healthy pMSCs. Mesenchymal stem cell metab-
olism is known to bemainly anaerobic. The shift toward an aerobic
mitochondrial metabolism is reported during differentiation, with
increase of mitochondrial biogenesis, oxygen consumption, and
Figure 7. Geneexpressionanalysisofmitochondrial biogenesis activator and respiratory chain complexes ofplacentalmesenchymal stromal cells
(pMSCs). Gene expression of NRF1 (mitochondrial biogenesis activator), UQCRC1, and COX4I1 (mitochondrial respiratory chain subunits) in pla-
centalmembrane- andplacental basal disk-derivedpMSCs isolated fromfivephysiological and six IUGRpregnancies.Relativeexpressionvaluesare
shown as box plots, indicating the median and the 25th and 75th percentiles. Abbreviation: IUGR, intrauterine growth restriction.
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ATP production [49]. Thus, mitochondrial modifications might ac-
count for thehigher adipogenic and the lowerendothelial differen-
tiation ability of pMSCs derived from IUGRplacentas. Interestingly,
pMSCs culturedwith no differentiatingmediumpresented a trend
toward higher NRF1, UQCRC1, and COX4I1 expression levels in
IUGRbasaldisc samplescomparedwithcontrols andhigherCOX4I1
levels in IUGR placental membranes. These differences were not
statistically significant, probably because of the low sample num-
ber. Nevertheless, they might account for metabolic alterations
in IUGR pMSCs, showing a possible shift to aerobic metabolism,
with the lossof themetabolic characteristics thatare typical ofmul-
tipotent and undifferentiated cells. This might be due to differ-
ences in oxygen concentrations within the placenta, occurring in
IUGR [50, 51], regulating mitochondrial biogenesis and function,
as previously observed in other animal tissues [52, 53].
We recently showed higher mitochondrial content in IUGR
placental tissue; this content was decreased in cytotrophoblast
cells isolated from the same placentas [18, 19]. We hypothesized
that other cell types may be responsible for the mitochondrial
content increase in the entire placental tissue, despite the de-
crease in cytotrophoblast cells. Here we suggest that pMSCs
might contribute to the global mitochondrial content increase
in IUGR compared with control placental tissues, possibly to-
gether with other placental cells, such as endothelial cells.
A potential limitation of this study is represented by the differ-
ent gestational age of the IUGR compared with the control group.
This is a limit of all studies comparing human IUGR to control term
placentas because IUGR pregnancies are electively delivered ear-
lier in the interest of the fetus. Another potential limitation is that
we investigated IUGR placentas at delivery, whereas placental ab-
normal development is supposed to start at the beginning of pla-
centation. Therefore, a cause-effect relationship may not be
inferred because the observed features might also be the conse-
quence of the altered placental environment influencing pMSCs.
In thedevelopingembryo, subtle changes in themicroenvironment
drive epigenetic change associated with cellular differentiation
[54]. However, this inherent sensitivity to external influence,which
is a hallmark of early development, potentially renders epigenetic
marks of pMSCs susceptible to external environmental influence.
Atpresent, no strongevidenceexists for a roleof epigenetic disrup-
tion as a driver of IUGR [55].
Interestingly, we demonstrated a fetal origin of the PM-
derived pMSCs and amaternal low contamination of PBD pMSCs.
These data agree with the literature [34, 56] and pointed out
whether maternal pMSCs may be involved in IUGR disease. Thus,
further studies are required to better understand the role of
pMSCs in IUGR and how environmental influence on placental
functioning modulate their regenerative capacities.
CONCLUSION
Theobserved IUGR-specific featuresmay indicate a role of pMSCs in
determining the specific placental phenotype associated with IUGR
pathogenesis. The loss of endothelial differentiation potential and
the increaseof adipogenic ability thatwe report are likely to contrib-
ute to the vicious cycle of abnormal placental development in IUGR.
These genuine new findings fit well with what is already known
about placental pathological features in IUGR. Targeting pMSCs
may thus lead to new perspectives for the treatment of IUGR.
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